Cracking the Case of a Deadly Type of Kidney Cancer

A research team led by Andrew Armstrong, MD, MSc, identifies new targets for treating non-clear cell renal carcinoma In 2016, a global multi-institutional team of investigators led by Duke Cancer Institute member and professor of Medicine, Surgery, Pharmacology and Cancer Biology, Andrew Armstrong, MD, MSc, reported in The Lancet their finding that a small-molecule drug (sunitinib) they’d trialed in patients […]

Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center.

Tyrosine kinase inhibitors (TKI) and immunotherapy improved survival in metastatic renal cell carcinoma (mRCC). Disparities in treatment access are present in healthcare systems globally. The aim of this study was to analyze survival outcomes of mRCC patients treated with first-line TKIs in the public (PHS) and private (PrS) health system in a Brazilian Cancer Center.

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.

To describe the study design of the GÖTEBORG prostate cancer screening (PC) 2 (Göteborg-2), a prospective, randomised, population-based trial of PC screening. This trial evaluates whether prostate-specific antigen (PSA) testing followed by 3 Tesla prostate magnetic resonance imaging (MRI) and targeted biopsy can reduce overdiagnosis, while maintaining the detection of clinically significant cancer, compared to […]

X